TGTX — TG Therapeutics, Inc.

TG Therapeutics Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• U.S. BRIUMVI Net Product Revenue: Approximately $228 million, representing a 64% year-over-year increase.
• Total Net Product Revenue: $240 million, which includes $4.5 million from licenses and royalties.
• Gross Margin: Approximately 87% for U.S. operations; total gross margin at 83%.
• Operating Income: $21.7 million; net income of $7.8 million ($0.05 per diluted share). Excluding manufacturing charges, adjusted operating income was about $76 million.
• Cash Position: Approximately $612 million in cash, cash equivalents, and investment securities.
• Updated Revenue Guidance: U.S. BRIUMVI net revenue expected to be between $890 million to $905 million, with total global revenue projected at approximately $950 million for 2026.

2. Strategic Updates and Business Highlights

• BRIUMVI Performance: Continued strong execution with record new patient starts and physician adoption, nearing a $1 billion annualized run rate.
• ENHANCE Study Results: Positive Phase III results showing that BRIUMVI can be initiated with a single 600-milligram infusion, expected to enhance patient convenience and potentially increase market share.
• Subcutaneous BRIUMVI: Positive Phase I bioavailability data reported, with a Phase III study fully enrolled and results expected by year-end or early next year. This formulation aims to expand the addressable market significantly.
• Expansion into Other Indications: Initiated studies for BRIUMVI in myasthenia gravis and treatment-resistant schizophrenia.
• Azer-cel Progress: Continued enrollment in the allogeneic CD19 CAR-T program, expanding to additional B-cell-mediated diseases.

3. Forward Guidance and Outlook

• Q3 and Q4 Expectations: Anticipated growth in Q4 to exceed $250 million in U.S. net revenue, setting the stage for a $1 billion annualized revenue run rate.
• Long-term Outlook: Confidence in BRIUMVI becoming a multibillion-dollar franchise, supported by ongoing innovation and expansion into new therapeutic areas.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: Increased competition in the anti-CD20 market, particularly from Roche's OCREVUS, which has led to a cautious outlook on market dynamics.
• Operational Challenges: Some operational expenses related to manufacturing for subcutaneous products could impact margins if not managed effectively.
• Market Dynamics: Potential seasonality and fluctuations in the MS market could affect revenue growth in Q3, with uncertainty about how these dynamics will play out.

5. Notable Q&A Insights

• Market Share Gains: BRIUMVI is gaining share from both treatment-naive patients and switches from OCREVUS, indicating strong brand confidence among physicians.
• Subcutaneous BRIUMVI Pricing: Pricing strategies for the subcutaneous formulation are still under evaluation, with expectations for competitive positioning against existing therapies.
• Persistence Trends: Higher-than-expected patient persistence on BRIUMVI is attributed to positive treatment experiences, which may enhance long-term brand loyalty.
• Business Development Strategy: TG Therapeutics is focused on strategic investments that maximize shareholder value, with an interest in acquiring single assets that complement their existing portfolio.

Overall, TG Therapeutics reported a strong quarter with significant revenue growth and strategic advancements, while acknowledging competitive pressures and operational challenges ahead.